Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

VARIFN

Financiado

VARIFN: Understanding variation in the type I interferon response and its impact...

VARIFN: Understanding variation in the type I interferon response and its impact on infection susceptibility in humans. Both antiviral immunity and susceptibility to viral infections are remarkably variable. Factors such as older age, increased body mass index, and male sex can increase the risk of developing severe viral disease, yet the impact of... ver más

30/04/2026

196K€

Presupuesto del proyecto: 196K€

Líder del proyecto

INSTITUT PASTEUR No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-03-26

HORIZON-MSCA-2023-PF-01-01: MSCA Postdoctoral Fellowships 2023 ExpectedOutcome:Project results are expected to contribute to the following outcomes:

I+D

Cerrada hace 1 año

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

195.91K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2009-08103 ESTIMULACION PAN-POBLACIONAL DE LA RESPUESTA DE LOS LINFOCIT... 88K€ Cerrado

ENVISION Novel mechanisms of early defense against virus infections 2M€ Cerrado

TIRI Role of the kinase TAOK2 in the innate immune response to vi... 174K€ Cerrado

SAF2012-39578 DESARROLLO DE NUEVAS ESTRATEGIAS TERAPEUTICAS PARA LA HEPATI... 133K€ Cerrado

CNS2023-143738 Biología molecular y celular 200K€ Cerrado

CoVICIS EU-Africa Concerted Action on SAR-CoV-2 Virus Variant and Im... 10M€ Cerrado

Duración del proyecto: 25 meses Fecha Inicio: 2024-03-26
Fecha Fin: 2026-04-30

Líder del proyecto

INSTITUT PASTEUR No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 196K€

Descripción del proyecto Both antiviral immunity and susceptibility to viral infections are remarkably variable. Factors such as older age, increased body mass index, and male sex can increase the risk of developing severe viral disease, yet the impact of these features on antiviral immunity, particularly the type I interferon system (IFN-I), is not understood. Here we propose to use a systems immunology approach to identify features that influence IFN-I responses and understand their impact on infection susceptibility. We will use datasets and samples from the Milieu Interieur (MI) cohort of 1000 donors consisting 500 males and 500 females aged 20-69 years old. Using Simoa digital ELISAs, we have quantified IFN-I (IFNa and IFNb) in the supernatants of whole blood from the 1000 donors that was stimulated ex vivo with 7 agonists that activate the IFN-I system. Preliminary analysis of these results shows interesting age and sex differences in the IFN-I response. We will integrate the IFN-I cytokine data with existing demographic, microbiome, immune cell phenotyping and plasma protein data from the cohort and determine their associations with IFN-I levels. To investigate sex differences in IFN-I we will quantify sex hormones in the plasma of the 1000 donors. We will perform RNA-sequencing on IFNa-stimulated whole blood on a subset (n=200) of the donors to investigate the factors that shape the response to IFNa itself. We will perform genome wide association studies of the IFN-I response in the cohort to identify variants that influence IFN-I production using SNP genotyping data from MI. To determine the impact of these features on IFN-I and influenza infectivity in vitro, we will develop an organ on chip model encompassing features that we find to be associated with IFN-I levels in MI. Results from this project will identify novel regulators of IFN-I and shed light on new strategies to boost the antiviral response to better protect against viral infection.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores